In children, drugs have boosted the cure rate of Wilm's tumor (a pediatric condition) to 80 percent. Unfortunately, progress is limited for recurrent kidney cancer; interleukin-2 and alpha interferon rarely produce complete remissions, and standard cytotoxic chemotherapy does not work.
As with other urologic cancers, scientists are searching for effective agents that improve survival, while producing fewer side effects. With no magic bullets expected, they are focused on finding targeted agents that can manipulate the molecular pathways that result in cancer. Advances in drug therapy will always be incorporated into progress with surgery and radiation therapy in order to give best results. Meticulous clinical trials are the only way to improve today's standard of care.
Whatever endurance it takes to finish this research race, the win will be worth the effort.